Epidermal Growth Factor Receptor Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
ALXO | A | ALX Oncology Holdings Inc. | -0.06 | |
BDTX | A | Black Diamond Therapeutics, Inc. | 15.26 | |
MACK | B | Merrimack Pharmaceuticals, Inc. | 0.00 | |
CNTA | D | Centessa Pharmaceuticals plc | -0.11 | |
PBYI | D | Puma Biotechnology Inc | 2.87 | |
AMGN | D | Amgen Inc. | 0.22 | |
OLMA | F | Olema Pharmaceuticals, Inc. | 1.22 | |
TCRT | F | Alaunos Therapeutics, Inc. | 13.79 | |
AFMD | F | Affimed Therapeutics B.V. | 3.07 | |
CKPT | F | Checkpoint Therapeutics, Inc. | 0.70 |
Related Industries: Biotechnology Drug Manufacturers - Major
Related ETFs - A few ETFs which own one or more of the above listed Epidermal Growth Factor Receptor stocks.
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BBH | D | Market Vectors Biotech ETF | 14.82 | |
IBBQ | D | Invesco Nasdaq Biotechnology ETF | 8.89 | |
IBB | D | iShares Nasdaq Biotechnology Index Fund | 8.62 | |
BIS | B | ProShares UltraShort Nasdaq Biotechnology | 8.14 | |
BIB | D | ProShares Ultra Nasdaq Biotechnology | 6.45 |
Compare ETFs
- Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.Epidermal growth factor and its receptor was discovered by Stanley Cohen of Vanderbilt University. Cohen shared the 1986 Nobel Prize in Medicine with Rita Levi-Montalcini for their discovery of growth factors.
Deficient signaling of the EGFR and other receptor tyrosine kinases in humans is associated with diseases such as Alzheimer's, while over-expression is associated with the development of a wide variety of tumors. Interruption of EGFR signalling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumours and improve the patient's condition.
Popular Now
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Featured Articles